About   Help   FAQ
Phenotypes associated with this allele
Allele Symbol
Allele Name
Allele ID 		Rnpc3tm1c(EUCOMM)Wtsi
targeted mutation 1c, Wellcome Trust Sanger Institute
MGI:6269405
Summary 2 genotypes
Jump to Allelic Composition Genetic Background Genotype ID
cn1
 		Ndor1Tg(UBC-cre/ERT2)1Ejb/Ndor1+
Rnpc3tm1c(EUCOMM)Wtsi/Rnpc3+ 		involves: 129S/SvEv * C57BL/6 * C57BL/6N MGI:6276274
cn2
 		Ndor1Tg(UBC-cre/ERT2)1Ejb/Ndor1+
Rnpc3tm1c(EUCOMM)Wtsi/Rnpc3tm1c(EUCOMM)Wtsi 		involves: 129S/SvEv * C57BL/6 * C57BL/6N MGI:6276277


Genotype
MGI:6276274
cn1
Allelic
Composition		 Ndor1Tg(UBC-cre/ERT2)1Ejb/Ndor1+
Rnpc3tm1c(EUCOMM)Wtsi/Rnpc3+
Genetic
Background		 involves: 129S/SvEv * C57BL/6 * C57BL/6N
Cell Lines EPD0441_1_B10
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Ndor1Tg(UBC-cre/ERT2)1Ejb mutation (6 available); any Ndor1 mutation (32 available)
Rnpc3tm1c(EUCOMM)Wtsi mutation (0 available); any Rnpc3 mutation (41 available)
♀ phenotype observed in females
♂ phenotype observed in males
N normal phenotype
normal phenotype
no abnormal phenotype detected ( J:267519 )
• tamoxifen-treated adult mice appear phenotypically normal with no significant weight loss relative to control mice




Genotype
MGI:6276277
cn2
Allelic
Composition		 Ndor1Tg(UBC-cre/ERT2)1Ejb/Ndor1+
Rnpc3tm1c(EUCOMM)Wtsi/Rnpc3tm1c(EUCOMM)Wtsi
Genetic
Background		 involves: 129S/SvEv * C57BL/6 * C57BL/6N
Cell Lines EPD0441_1_B10
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Ndor1Tg(UBC-cre/ERT2)1Ejb mutation (6 available); any Ndor1 mutation (32 available)
Rnpc3tm1c(EUCOMM)Wtsi mutation (0 available); any Rnpc3 mutation (41 available)
♀ phenotype observed in females
♂ phenotype observed in males
N normal phenotype
mortality/aging
moribund ( J:267519 )
• at 8 days after tamoxifen (TAM) treatment, adult mice show signs of malnutrition and stress (scruffy coat, docile, and hunched behavior) requiring euthanasia

growth/size/body
weight loss ( J:267519 )
• adult mice show irreversible weight loss by 6 days after TAM treatment

behavior/neurological
hunched posture ( J:267519 )
• hunched behavior at 8 days after TAM treatment

immune system
small intestinal inflammation ( J:267519 )
• infiltration of immune cells in small intestinal epithelium at 6 days after TAM treatment
esophageal inflammation ( J:267519 )
• signs of erosive esophagitis at 8 days after TAM treatment
decreased thymus weight ( J:267519 )
• significant reduction in thymus weight at 8 days at 8 days after TAM treatment
thymus atrophy ( J:267519 )
• significantly smaller thymus with no discernible medullary or cortical regions at 8 days after TAM treatment
thymus cortex atrophy ( J:267519 )
• at 8 days after TAM treatment
thymus medulla atrophy ( J:267519 )
• at 8 days after TAM treatment
decreased leukocyte cell number ( J:267519 )
• significant leucopenia at 8 days after TAM treatment
decreased lymphocyte cell number ( J:267519 )
• significant decrease in lymphocyte number at 8 days after TAM treatment
decreased monocyte cell number ( J:267519 )
• significant decrease in monocyte number at 8 days after TAM treatment

digestive/alimentary system
increased small intestinal crypt cell apoptosis ( J:267519 )
• significant increase in the number of apoptotic cells in the highly proliferative, stem/progenitor compartment of the small intestinal crypts at 2 and 4 days after TAM treatment
abnormal enterocyte proliferation ( J:267519 )
• reduced cell proliferation in the proliferative compartment of the small intestinal epithelium at 4 days after TAM treatment
abnormal small intestinal crypt cell proliferation ( J:267519 )
• marked reduction in BrdU+ cells in small intestinal crypts at 4 days after TAM treatment
• new BrdU+ crypt-like structures corresponding to sites of regeneration at 6 and 8 days after TAM treatment
abnormal digestive system morphology ( J:267519 )
• severe atrophy of the entire gastrointestinal epithelium with mucosa disruption from the esophagus to the rectum at 8 days after TAM treatment
• extensive degeneration of the epithelial layer interspersed with discrete pockets of regenerating crypt-like structures
abnormal esophageal squamous epithelium morphology ( J:267519 )
• disrupted organization of the squamous epithelium of the esophagus at 8 days after TAM treatment
abnormal intestinal epithelium morphology ( J:267519 )
• at 8 days after TAM treatment, the epithelial monolayer lining the small intestine and colon contains vacuolated epithelial cells scattered throughout the submucosa; epithelial layer degeneration is intermixed with discrete pockets of regenerating crypt-like structures
• loss of epithelial integrity in the small intestine and colon with nuclei rounding up and cells losing apico-basal polarity at 4 days after TAM treatment
• highly disorganized small intestine epithelium, with crypt loss, decreased villus height, infiltration of immune cells, and ulceration at 6 days after TAM treatment
• thinner and flatter epithelial cells in the colon at 6 days after TAM treatment
abnormal intestinal mucosa morphology ( J:267519 )
• at 8 days after TAM treatment
abnormal large intestine crypts of Lieberkuhn morphology ( J:267519 )
• loss of crypt structure in the colon at 4 days after TAM treatment
• large vacuolated spaces in colonic crypts at 6 days after TAM treatment
abnormal small intestine crypts of Lieberkuhn morphology ( J:267519 )
• loss of crypt structure in the small intestine at 4 days after TAM treatment
decreased small intestinal villus height ( J:267519 )
• reduced villus height in the small intestine at 6 days after TAM treatment
abnormal stomach glandular epithelium morphology ( J:267519 )
• degeneration of columnar mucous epithelium of the glandular stomach at 8 days after TAM treatment
small intestinal inflammation ( J:267519 )
• infiltration of immune cells in small intestinal epithelium at 6 days after TAM treatment
esophageal inflammation ( J:267519 )
• signs of erosive esophagitis at 8 days after TAM treatment

hematopoietic system
decreased thymus weight ( J:267519 )
• significant reduction in thymus weight at 8 days at 8 days after TAM treatment
thymus atrophy ( J:267519 )
• significantly smaller thymus with no discernible medullary or cortical regions at 8 days after TAM treatment
thymus cortex atrophy ( J:267519 )
• at 8 days after TAM treatment
thymus medulla atrophy ( J:267519 )
• at 8 days after TAM treatment
anemia ( J:267519 )
• significant anemia at 8 days after TAM treatment
decreased erythrocyte cell number ( J:267519 )
• significant decrease in RBC number at 8 days after TAM treatment
thrombocytopenia ( J:267519 )
• severe thrombocytopenia at 8 days after TAM treatment
decreased leukocyte cell number ( J:267519 )
• significant leucopenia at 8 days after TAM treatment
decreased lymphocyte cell number ( J:267519 )
• significant decrease in lymphocyte number at 8 days after TAM treatment
decreased monocyte cell number ( J:267519 )
• significant decrease in monocyte number at 8 days after TAM treatment

integument
sebaceous gland atrophy ( J:267519 )
• paucity of sebaceous glands at 8 days after TAM treatment
disheveled coat ( J:267519 )
• scruffy coat at 8 days at 8 days after TAM treatment
abnormal skin morphology ( J:267519 )
• mild skin abnormalities at 8 days after TAM treatment
epidermal atrophy ( J:267519 )
• attenuated epidermis at 8 days after TAM treatment

endocrine/exocrine glands
abnormal large intestine crypts of Lieberkuhn morphology ( J:267519 )
• loss of crypt structure in the colon at 4 days after TAM treatment
• large vacuolated spaces in colonic crypts at 6 days after TAM treatment
abnormal small intestine crypts of Lieberkuhn morphology ( J:267519 )
• loss of crypt structure in the small intestine at 4 days after TAM treatment
decreased thymus weight ( J:267519 )
• significant reduction in thymus weight at 8 days at 8 days after TAM treatment
thymus atrophy ( J:267519 )
• significantly smaller thymus with no discernible medullary or cortical regions at 8 days after TAM treatment
thymus cortex atrophy ( J:267519 )
• at 8 days after TAM treatment
thymus medulla atrophy ( J:267519 )
• at 8 days after TAM treatment
sebaceous gland atrophy ( J:267519 )
• paucity of sebaceous glands at 8 days after TAM treatment

cellular
increased small intestinal crypt cell apoptosis ( J:267519 )
• significant increase in the number of apoptotic cells in the highly proliferative, stem/progenitor compartment of the small intestinal crypts at 2 and 4 days after TAM treatment
abnormal enterocyte proliferation ( J:267519 )
• reduced cell proliferation in the proliferative compartment of the small intestinal epithelium at 4 days after TAM treatment
abnormal small intestinal crypt cell proliferation ( J:267519 )
• marked reduction in BrdU+ cells in small intestinal crypts at 4 days after TAM treatment
• new BrdU+ crypt-like structures corresponding to sites of regeneration at 6 and 8 days after TAM treatment




Contributing Projects:
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB)), Gene Ontology (GO)
Citing These Resources
Funding Information
Warranty Disclaimer, Privacy Notice, Licensing, & Copyright
Send questions and comments to User Support. 		last database update
11/12/2024
MGI 6.24 		The Jackson Laboratory